Informations:
Erreur:
ID
37245
Description
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026); ODM derived from: https://clinicaltrials.gov/show/NCT02041533
Lien
https://clinicaltrials.gov/show/NCT02041533
Mots-clés
Versions (1)
- 11/07/2019 11/07/2019 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
11 juillet 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Stage IV or Recurrent Non-Small Cell Lung Cancer NCT02041533
Eligibility Stage IV or Recurrent Non-Small Cell Lung Cancer NCT02041533
- StudyEvent: Eligibility
Similar models
Eligibility Stage IV or Recurrent Non-Small Cell Lung Cancer NCT02041533
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status (ps) ≤ 1
boolean
C1520224 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma TNM clinical staging | Non-small cell lung cancer recurrent | Cancer treatment Systemic Absent
Item
histologically confirmed stage iv, or recurrent nsclc with no prior systemic anticancer therapy
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0278517 (UMLS CUI [2])
C0920425 (UMLS CUI [3,1])
C0205373 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
C3258246 (UMLS CUI [1,2])
C0278517 (UMLS CUI [2])
C0920425 (UMLS CUI [3,1])
C0205373 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
Measurable Disease CT | Measurable Disease MRI
Item
measurable disease by computed tomography (ct) or magnetic resonance imaging (mri) per response evaluation criteria in solid tumors version (recist) 1.1 criteria
boolean
C1513041 (UMLS CUI [1,1])
C0040405 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2,1])
C0024485 (UMLS CUI [2,2])
C0040405 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2,1])
C0024485 (UMLS CUI [2,2])
PD-L1 Positive Immunohistochemistry
Item
pd-l1+ on immunohistochemistry testing performed by central lab
boolean
C4284303 (UMLS CUI [1,1])
C0021044 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,2])
Age
Item
men and women, ages ≥ 18 years of age
boolean
C0001779 (UMLS CUI [1])
EGFR gene mutation | Sensitive Inhibitor Targeted Therapy
Item
known epidermal growth factor receptor (egfr) mutations which are sensitive to available targeted inhibitor therapy
boolean
C3266992 (UMLS CUI [1])
C0332324 (UMLS CUI [2,1])
C1999216 (UMLS CUI [2,2])
C2985566 (UMLS CUI [2,3])
C0332324 (UMLS CUI [2,1])
C1999216 (UMLS CUI [2,2])
C2985566 (UMLS CUI [2,3])
ALK Gene Translocation
Item
known anaplastic lymphoma kinase (alk) translocations
boolean
C4329227 (UMLS CUI [1])
CNS metastases Untreated
Item
untreated central nervous system (cns) metastases
boolean
C0686377 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0332155 (UMLS CUI [1,2])
Malignant Neoplasms Previous
Item
previous malignancies
boolean
C0006826 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,2])
Autoimmune Disease | Autoimmune Disease Suspected
Item
active, known or suspected autoimmune disease
boolean
C0004364 (UMLS CUI [1])
C0004364 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0004364 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])